Bolstering FDA Pathways for Reducing Death and Disease from Tobacco

The Family Smoking Prevention and Tobacco Control Act has led to a 26% decrease in cigarette use since 2009. The FDA plays a crucial role in enforcing the law to promote public health, but the slowdown in smoking decline poses challenges. FDA-approved nicotine products like gums and patches aid cessation. The Modified Risk Tobacco Product pathway allows for less harmful alternatives, but balancing benefits for smokers and risks for youth is essential. FDA must address backlogs in product applications to regulate and enforce marketing restrictions effectively. Implementing the TCA fully, including regulating nicotine levels in cigarettes, is crucial for combating addiction and reducing smoking-related harm.